Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

“Mini-mental state”

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · see citing works

An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest

Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324 · see citing works

The Clinical Dementia Rating (CDR): Current version and scoring rules

Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882 · see citing works

Co-planar stereotaxic atlas of the human brain : 3-dimensional proportional system : an approach to cerebral imaging

Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058 · see citing works

Manual for the Wechsler Adult Intelligence Scale.

Wechsler, D. (1955) · Psychological Corp. eBooks · Cited by 4,941 · see citing works

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · see citing works

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065 · see citing works

Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease

Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., & Berg, L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.397 · Cited by 1,833 · see citing works

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works

Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data

Logan, J., Fowler, J. S., Volkow, N. D., Wang, G., Ding, Y., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,515 · see citing works

Neuropathology of older persons without cognitive impairment from two community-based studies

Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336 · see citing works

A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume

Buckner, R. L., Head, D. M., Parker, J. B., Fotenos, A. F., Marcus, D. S., Morris, J. C., & Snyder, A. Z. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.06.018 · Cited by 1,290 · see citing works

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ ₄₂ in humans

Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246 · see citing works

The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals

Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153 · see citing works

Imaging β-amyloid burden in aging and dementia

Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104 · see citing works

Frequent amyloid deposition without significant cognitive impairment among the elderly

Aizenstein, H. J., Nebes, R. D., Saxton, J. A., Price, J. C., Mathis, C. A., Tsopelas, N. D., Ziolko, S. K., James, J. A., Snitz, B. E., Houck, P. R., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1509 · Cited by 1,059 · see citing works

[ ¹¹ C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

Mintun, M. A., LaRossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., Klunk, W. E., Mathis, C. A., DeKosky, S. T., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228230.26044.a4 · Cited by 1,036 · see citing works

Synthesis and Evaluation of 11C-Labeled 6-Substituted 2-Arylbenzothiazoles as Amyloid Imaging Agents

Mathis, C. A., Wang, Y., Holt, D. P., Huang, G.-F., Debnath, M. L., & Klunk, W. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030026b · Cited by 976 · see citing works

The Uniform Data Set (UDS): Clinical and Cognitive Variables and Descriptive Data From Alzheimer Disease Centers

Morris, J. C., Weintraub, S., Chui, H. C., Cummings, J., DeCarli, C., Ferris, S., Foster, N. L., Galasko, D., Graff-Radford, N., Peskind, E. R., et al. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213865.09806.92 · Cited by 950 · see citing works

Cerebrospinal Fluid tau/β-Amyloid42 Ratio as a Prediction of Cognitive Decline in Nondemented Older Adults

Fagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · see citing works

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

Tapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896 · see citing works

<i>APOE</i> predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging

Morris, J. C., Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., & Mintun, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.21843 · Cited by 830 · see citing works

-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., Mathis, C. A., Klunk, W. E., Masters, C. L., & Rowe, C. C. (2007) · Brain · doi:10.1093/brain/awm238 · Cited by 789 · see citing works

PET imaging of amyloid deposition in patients with mild cognitive impairment

Forsberg, A., Engler, H., Almkvist, O., Blomquist, G., Hagman, G., Wall, A. E., Ringheim, A., Långström, B., & Nordberg, A. K. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.03.029 · Cited by 725 · see citing works

Reduction of β‐amyloid peptide₄₂ in the cerebrospinal fluid of patients with Alzheimer's disease

Motter, R., Vigo‐Pelfrey, C., Kholodenko, D., Barbour, R., Johnson‐Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410380413 · Cited by 701 · see citing works

DSM‐IV‐TR: Diagnostic and Statistical Manual of Mental Disorders

Chao, R., & Manita, J. (2013) · The Encyclopedia of Cross‐Cultural Psychology · doi:10.1002/9781118339893.wbeccp180 · Cited by 683 · see citing works

Neuropathology of Cognitively Normal Elderly

Knopman, D. S., Parisi, J. E., Salviati, A., Floriach-Robert, M., Boeve, B. F., Ivnik, R. J., Smith, G. E., Dickson, D. W., Johnson, K. A., Petersen, L. E., et al. (2003) · Journal of Neuropathology &amp; Experimental Neurology · doi:10.1093/jnen/62.11.1087 · Cited by 674 · see citing works

Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease

Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · see citing works

Clinicopathologic Studies in Cognitively Healthy Aging and Alzheimer Disease: Relation of Histologic Markers to Dementia Severity, Age, Sex, and Apolipoprotein E Genotype

Berg, L., McKeel, D. W., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., Baty, J., Coats, M., Norton, J., Goate, A. M., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.326 · Cited by 657 · see citing works

Decreased β-Amyloid_1-42and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease

Sunderland, T., Linker, G., Mirza, N., Putnam, K. T., Friedman, D. L., Kimmel, L. H., Bergeson, J., Manetti, G. J., Zimmermann, M., Tang, B., et al. (2003) · JAMA · doi:10.1001/jama.289.16.2094 · Cited by 656 · see citing works

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study

Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614 · see citing works

Neuron Number in the Entorhinal Cortex and CA1 in Preclinical Alzheimer Disease

Price, J. L., Ko, A. I., Wade, M. J., Tsou, S. K., McKeel, D. W., & Morris, J. C. (2001) · Archives of Neurology · doi:10.1001/archneur.58.9.1395 · Cited by 596 · see citing works

MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths

Jovicich, J., Czanner, S., Han, X., Salat, D. H., van der Kouwe, A. J. W., Quinn, B. T., Pacheco, J., Albert, M., Killiany, R., & Blacker, D. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.02.010 · Cited by 549 · see citing works

An analysis of certain psychological tests used for the evaluation of brain injury.

Armitage, S. G. (1946) · The Psychological Monographs · doi:10.1037/h0093567 · Cited by 518 · see citing works

Very mild Alzheimer's disease: Informant‐based clinical, psychometric, and pathologic distinction from normal aging

Morris, J. C., McKeel, D. W., Storandt, M., Rubin, E. H., Price, J. L., Grant, E. A., Ball, M. J., & Berg, L. (1991) · Neurology · doi:10.1212/wnl.41.4.469 · Cited by 473 · see citing works

Memory impairment on free and cued selective reminding predicts dementia

Grober, E. H., Lipton, R. B., Hall, C. B., & Crystal, H. (2000) · Neurology · doi:10.1212/wnl.54.4.827 · Cited by 393 · see citing works

Cerebrospinal Fluid Tau and β-Amyloid: How Well Do These Biomarkers Reflect Autopsy-Confirmed Dementia Diagnoses?

Clark, C. M., Xie, S., Chittams, J., Ewbank, D., Peskind, E., Galasko, D., Morris, J. C., McKeel, D. W., Farlow, M., Weitlauf, S. L., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1696 · Cited by 357 · see citing works

Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353 · see citing works

Amyloid imaging in mild cognitive impairment subtypes

Wolk, D. A., Price, J. C., Saxton, J. A., Snitz, B. E., James, J. A., López, O. L., Aizenstein, H. J., Cohen, A. D., Weissfeld, L. A., Mathis, C. A., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21598 · Cited by 339 · see citing works

Decreased cerebrospinal fluid Aβ ₄₂ correlates with brain atrophy in cognitively normal elderly

Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327 · cited 2× · see citing works

Cognitive Decline and Brain Volume Loss as Signatures of Cerebral Amyloid-β Peptide Deposition Identified With Pittsburgh Compound B

Storandt, M., Mintun, M. A., Head, D. M., & Morris, J. C. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.272 · Cited by 304 · see citing works

Longitudinal Study of the Transition From Healthy Aging to Alzheimer Disease

Johnson, D. K., Storandt, M., Morris, J. C., & Galvin, J. E. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.158 · Cited by 301 · see citing works

Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI

Storandt, M., Grant, E., Miller, J. P., & Morris, J. C. (2006) · Neurology · doi:10.1212/01.wnl.0000228231.26111.6e · Cited by 285 · see citing works

CSF tau/Aβ 42 ratio for increased risk of mild cognitive impairment

Li, G., Sokal, I., Quinn, J. F., Leverenz, J. B., Brodey, M., Schellenberg, G. D., Kaye, J. A., Raskind, M. A., Zhang, J., Peskind, E. R., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000267428.62582.aa · Cited by 274 · see citing works

Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve.

Fotenos, A. F., Mintun, M., Snyder, A., Morris, J., & Buckner, R. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.27 · Cited by 228 · see citing works

Alzheimer Disease and Cognitive Reserve

Roe, C. M., Mintun, M. A., D’Angelo, G., Xiong, C., Grant, E., & Morris, J. C. (2008) · Archives of Neurology · doi:10.1001/archneur.65.11.1467 · Cited by 215 · see citing works

Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease

Cairns, N. J., Ikonomović, M. D., Benzinger, T. L. S., Storandt, M., Fagan, A. M., Shah, A. R., Taylor‐Reinwald, L., Carter, D. R., Felton, A., Holtzman, D. M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.279 · Cited by 203 · see citing works

Higher atrophy rate of entorhinal cortex than hippocampus in AD

Du, A., Schuff, N. W., Kramer, J. H., Ganzer, S., Zhu, X., Jagust, W. J., Miller, B. L., Reed, B., Mungas, D., Yaffe, K. S., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000106462.72282.90 · Cited by 201 · see citing works

Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds

Skoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068478 · Cited by 194 · see citing works

Apolipoprotein Eε4 modifies Alzheimer's disease onset in an E280A PS1 kindred

Pastor, P., Roe, C. M., Villegas, A., Bedoya, G., Chakraverty, S., García, G., Tirado, V., Norton, J., Ríos, S., Martínez, M., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10636 · Cited by 194 · see citing works

CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment

Herukka, S., Hallikainen, M., Soininen, H. S., & Pirttilä, T. (2005) · Neurology · doi:10.1212/01.wnl.0000156914.16988.56 · Cited by 189 · see citing works

MRI predictors of risk of incident Alzheimer disease

Stoub, T. R., Bulgakova, M., Leurgans, S. E., Bennett, D. A., Fleischman, D. A., Turner, D. A., & deToledo‐Morrell, L. (2005) · Neurology · doi:10.1212/01.wnl.0000160089.43264.1a · Cited by 188 · see citing works

Frontal-Hippocampal Double Dissociation Between Normal Aging and Alzheimer's Disease

Head, D. M., Snyder, A. Z., Girton, L. E., Morris, J. C., & Buckner, R. L. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh174 · Cited by 158 · see citing works

Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI

Ewers, M., Büerger, K., Teipel, S. J., Scheltens, P., Schröder, J., Zinkowski, R. P., Bouwman, F. H., Schönknecht, P., Schoonenboom, N. S. M., Andreasen, N. C., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000286944.22262.ff · Cited by 142 · see citing works

Preclinical Evidence of Alzheimer Changes

Petrie, E. C., Cross, D. J., Galasko, D. R., Schellenberg, G. D., Raskind, M. A., Peskind, E. R., & Minoshima, S. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.59 · Cited by 101 · see citing works

The Assessment of Aphasia & Related Disorders. Second Edition. Edited by H. Goodglass and E. Kaplan. Published by Lea & Febiger. 102 pages. Additional materials: A Boston Diagnostic Aphasia Examination booklet, copy bound in the book (32 pages); test stimulus cards (16); the Boston Naming Test (64 pages); Boston Naming Test scoring booklet (8 pages). $34.50 Canadian.

KERTESZ, A. E. (1984) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100045868 · Cited by 67 · see citing works

Antecedent Biomarkers of Alzheimer’s Disease: The Adult Children Study

Coats, M., & Morris, J. C. (2005) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988705281881 · Cited by 44 · see citing works

Untitled work

Price (1999) · doi:10.1002/1531-8249(199903)45:3

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · see citing works

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321 · see citing works

Alzheimer Disease: An Update on Pathobiology and Treatment Strategies

Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · see citing works

Revising the definition of Alzheimer's disease: a new lexicon

Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869 · see citing works

Alzheimer's disease

Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853 · see citing works

Alzheimer Mechanisms and Therapeutic Strategies

Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758 · see citing works

Alzheimer’s Disease Neuroimaging Initiative

Mueller, S. G., Weiner, M. W., Thal, L. J., Petersen, R. C., Jack, C. R., Jagust, W. J., Trojanowski, J. Q., Toga, A. W., & Beckett, L. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-72076-0_18 · Cited by 1,493 · see citing works

Alzheimer’s Disease: The Challenge of the Second Century

Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · see citing works

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

Clark, C. M. (2011) · JAMA · doi:10.1001/jama.2010.2008 · Cited by 1,117 · see citing works

Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

Spangenberg, E., Severson, P. L., Hohsfield, L. A., Crapser, J., Zhang, J., Burton, E. A., Zhang, Y., Spevak, W., Lin, J., Phan, N. Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11674-z · Cited by 939 · see citing works

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885 · see citing works

The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline

Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860 · see citing works

Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association

Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2013.01.002 · Cited by 603 · see citing works

An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease

Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22628 · Cited by 602 · see citing works

Peripherally Applied Aβ-Containing Inoculates Induce Cerebral β-Amyloidosis

Eisele, Y. S., Obermüller, U., Heilbronner, G., Baumann, F., Kaeser, S. A., Wolburg, H., Walker, L. C., Staufenbiel, M., Heikenwalder, M., & Jucker, M. (2010) · Science · doi:10.1126/science.1194516 · Cited by 568 · see citing works

The Alzheimer’s Disease Mitochondrial Cascade Hypothesis

Swerdlow, R. H., Burns, J. M., & Khan, S. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100339 · Cited by 562 · see citing works

Alzheimer Disease

Castellani, R. J., Rolston, R. K., & Smith, M. A. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2010.06.001 · Cited by 561 · see citing works

Testing the Right Target and Right Drug at the Right Stage

Sperling, R. A., Jack, C. R., & Aisen, P. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002609 · Cited by 550 · see citing works

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

Jack, C. R., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G., Bernstein, M. A., Gunter, J. L., Pankratz, V. S., Aisen, P. S., et al. (2010) · Brain · doi:10.1093/brain/awq277 · Cited by 531 · see citing works

Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease

Morris, G. P., Clark, I. A., & Vissel, B. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0135-5 · Cited by 522 · see citing works

Resting state functional connectivity in preclinical Alzheimer’s disease

Sheline, Y. I., & Raichle, M. E. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.11.028 · Cited by 509 · see citing works

Lipid peroxidation triggers neurodegeneration: A redox proteomics view into the Alzheimer disease brain

Sultana, R., Perluigi, M., & Butterfield, D. A. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.09.027 · Cited by 478 · see citing works

Probing the biology of Alzheimer’s disease in mice

Ashe, K. H., & Zahs, K. R. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.031 · Cited by 413 · see citing works

The benefits and limitations of animal models for translational research in neurodegenerative diseases

Jucker, M. (2010) · Nature Medicine · doi:10.1038/nm.2224 · Cited by 401 · see citing works

Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults

Dickerson, B. C., Stoub, T. R., Shah, R. C., Sperling, R. A., Killiany, R., Albert, M., Hyman, B. T., Blacker, D., & deToledo‐Morrell, L. (2011) · Neurology · doi:10.1212/wnl.0b013e3182166e96 · Cited by 380 · see citing works

Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden

Drzezga, A. E., Becker, J. A., Dijk, K. R. A. V., Sreenivasan, A., Talukdar, T., Sullivan, C., Schultz, A. P., Sepulcre, J., Putcha, D., Greve, D. N., et al. (2011) · Brain · doi:10.1093/brain/awr066 · Cited by 377 · see citing works

Amyloid Imaging with18F-Florbetaben in Alzheimer Disease and Other Dementias

Villemagne, V. L., Ong, K. T., Mulligan, R. S., Holl, G., Pejoska, S., Jones, G. R., O'Keefe, G. J., Ackerman, U., Tochon‐Danguy, H., Chan, J. G., et al. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.089730 · Cited by 374 · see citing works

Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans

Cirrito, J. R., Disabato, B. M., Restivo, J. L., Verges, D. K., Goebel, W. D., Sathyan, A., Hayreh, D., D'Angelo, G., Benzinger, T., Yoon, H., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1107411108 · Cited by 370 · see citing works

Gut microbiome composition may be an indicator of preclinical Alzheimer’s disease

Ferreiro, A. L., Choi, J., Ryou, J., Newcomer, E. P., Thompson, R., Bollinger, R. M., Hall-Moore, C. M., Ndao, I. M., Sax, L., Benzinger, T. L. S., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo2984 · Cited by 369 · see citing works

Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease

Fagan, A. M., Mintun, M. A., Shah, A. R., Aldea, P., Roe, C. M., Mach, R. H., Marcus, D., Morris, J. C., & Holtzman, D. M. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900048 · Cited by 353 · see citing works

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease

Chételat, G., Joie, R. L., Villain, N., Perrotin, A., Sayette, V. D. L., Eustache, F., & Vandenberghe, R. R. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.02.006 · Cited by 353 · see citing works

Amyloid‐β associated cortical thinning in clinically normal elderly

Becker, J. A., Hedden, T., Carmasin, J., Maye, J., Rentz, D. M., Putcha, D., Fischl, B., Greve, D. N., Marshall, G. A., Salloway, S., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22333 · Cited by 342 · see citing works

Relationships between Beta-Amyloid and Functional Connectivity in Different Components of the Default Mode Network in Aging

Mormino, E. C., Smiljic, A., Hayenga, A. O., Onami, S. H., Greicius, M. D., Rabinovici, G. D., Janabi, M., Baker, S. L., Yen, I. V., Madison, C. M., et al. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr025 · Cited by 332 · see citing works

Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association

Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H., Rowe, C. C., Carrillo, M. C., Hartley, D. M., et al. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120618 · Cited by 329 · see citing works

The future of blood‐based biomarkers for Alzheimer's disease

Henriksen, K., O’Bryant, S. E., Hampel, H. J., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss‐Coray, T., Soares, H. D., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.013 · Cited by 312 · see citing works

Brain aging, Alzheimer's disease, and mitochondria

Swerdlow, R. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.012 · Cited by 306 · see citing works

Retinal vascular biomarkers for early detection and monitoring of Alzheimer’s disease

Frost, S., Kanagasingam, Y., Sohrabi, H., Vignarajan, J., Bourgeat, P., Salvado, O., Villemagne, V, Rowe, C. C., Lance Macaulay, S., Szoeke, C., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.150 · Cited by 297 · see citing works

Preclinical Alzheimer disease—the challenges ahead

Sperling, R. A., Karlawish, J., & Johnson, K. A. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.241 · Cited by 291 · see citing works

Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease

Mormino, E. C., Betensky, R. A., Hedden, T., Schultz, A. P., Ward, A. M., Huijbers, W., Rentz, D. M., Johnson, K. A., Sperling, R. A., & For the Alzheimer's Disease Neuroimaging Initiative, T. A. I. B. A. L. F. S. O. A. (2014) · Neurology · doi:10.1212/wnl.0000000000000431 · Cited by 290 · see citing works

Structural Imaging Measures of Brain Aging

Lockhart, S. N., & DeCarli, C. S. (2014) · Neuropsychology Review · doi:10.1007/s11065-014-9268-3 · Cited by 272 · see citing works

Untitled work

Head (2012) · doi:10.1001/archneurol.2011.845 · Cited by 267 · see citing works

Face-name associative memory performance is related to amyloid burden in normal elderly

Rentz, D. M., Amariglio, R. E., Becker, J. A., Frey, M., Olson, L. E., Frishe, K., Carmasin, J. S., Maye, J. E., Johnson, K. A., & Sperling, R. A. (2011) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2011.06.006 · Cited by 264 · see citing works

Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection

Teipel, S. J., Drzezga, A. E., Grothe, M. J., Barthel, H., Chételat, G., Schuff, N. W., Skudlarski, P., Cavedo, E., Frisoni, G. B., Hoffmann, W. U., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00093-9 · Cited by 263 · see citing works

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer’s disease: a voxelwise PiB–PET longitudinal study

Villain, N., Chételat, G., Grassiot, B., Bourgeat, P., Jones, G., Ellis, K. A., Ames, D., Martins, R. N., Eustache, F., Salvado, O., et al. (2012) · Brain · doi:10.1093/brain/aws125 · Cited by 255 · see citing works

Structural MRI changes detectable up to ten years before clinical Alzheimer's disease

Tondelli, M., Wilcock, G. K., Nichelli, P., de Jager, C. A., Jenkinson, M., & Zamboni, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.018 · Cited by 251 · see citing works

Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression

Huijbers, W., Mormino, E. C., Schultz, A. P., Wigman, S. E., Ward, A. M., Larvie, M., Amariglio, R. E., Marshall, G. A., Rentz, D. M., Johnson, K. A., et al. (2015) · Brain · doi:10.1093/brain/awv007 · Cited by 247 · see citing works

Quantitative Analysis of PiB-PET with FreeSurfer ROIs

Su, Y., D'Angelo, G. M., Vlassenko, A. G., Zhou, G., Snyder, A. Z., Marcus, D. S., Blazey, T. M., Christensen, J. J., Vora, S., Morris, J. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073377 · Cited by 246 · see citing works

MRI cortical thickness biomarker predicts AD-like CSF and cognitive decline in normal adults

Dickerson, B. C., & Wolk, D. A. (2011) · Neurology · doi:10.1212/wnl.0b013e31823efc6c · Cited by 243 · see citing works

Clinical amyloid imaging in Alzheimer's disease

Herholz, K., & Ebmeier, K. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70123-5 · Cited by 240 · see citing works

The effects of aging and Alzheimer's disease on cerebral cortical anatomy: Specificity and differential relationships with cognition

Bakkour, A., Morris, J. C., Wolk, D. A., & Dickerson, B. C. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.02.059 · Cited by 240 · see citing works

Multimodality Review of Amyloid-related Diseases of the Central Nervous System

Miller‐Thomas, M. M., Sipe, A. L., Benzinger, T. L. S., McConathy, J., Connolly, S., & Schwetye, K. E. (2016) · Radiographics · doi:10.1148/rg.2016150172 · Cited by 234 · see citing works

Apolipoprotein E and Alzheimer’s disease: Findings, hypotheses, and potential mechanisms

Koutsodendris, N., Nelson, M. R., Rao, A., & Huang, Y. (2022) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-030421-112756 · Cited by 231 · see citing works

Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors

Tayeb, H. O., Yang, H. D., Price, B. H., & Tarazi, F. I. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.12.002 · Cited by 231 · see citing works

Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline

Doraiswamy, P. M., Sperling, R. A., Coleman, R. E., Johnson, K. A., Reiman, E. M., Davis, M. D., Grundman, M., Sabbagh, M. N., Sadowsky, C., Fleisher, A., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661f74 · Cited by 228 · see citing works

Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease

Morgan, D. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02315.x · Cited by 225 · see citing works

Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later

Roe, C. M., Fagan, A. M., Grant, E. A., Hassenstab, J., Moulder, K. L., Maue Dreyfus, D., Sutphen, C. L., Benzinger, T. L. S., Mintun, M. A., Holtzman, D. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182918ca6 · Cited by 222 · see citing works

Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing

Rowe, C. C., Bourgeat, P., Ellis, K. A., Brown, B., Lim, Y. Y., Mulligan, R., Jones, G., Maruff, P., Woodward, M., Price, R., et al. (2013) · Annals of Neurology · doi:10.1002/ana.24040 · Cited by 222 · see citing works

Evidence for Ordering of Alzheimer Disease Biomarkers

Jack, C. R. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.183 · Cited by 221 · see citing works

Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer's disease

Mielke, M. M., Okonkwo, O. C., Oishi, K., Mori, S., Tighe, S. K., Miller, M. I., Ceritoglu, C., Brown, T., Albert, M., & Lyketsos, C. G. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.05.2416 · Cited by 209 · see citing works

Developing an international network for Alzheimer’s research: the Dominantly Inherited Alzheimer Network

Morris, J. C., Aisen, P. S. S., Bateman, R. J., Benzinger, T. L. S., Cairns, N. J., Fagan, A. M., Ghetti, B. F., Goate, A., Holtzman, D. M., Klunk, W. E., et al. (2012) · Clinical Investigation · doi:10.4155/cli.12.93 · Cited by 205 · see citing works

Absence of Pittsburgh Compound B Detection of Cerebral Amyloid β in a Patient With Clinical, Cognitive, and Cerebrospinal Fluid Markers of Alzheimer Disease

Cairns, N. J., Ikonomović, M. D., Benzinger, T. L. S., Storandt, M., Fagan, A. M., Shah, A. R., Taylor‐Reinwald, L., Carter, D. R., Felton, A., Holtzman, D. M., et al. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.279 · Cited by 203 · see citing works

Predicting MCI outcome with clinically available MRI and CSF biomarkers

Heister, D. S., Brewer, J. B., Magda, S., Blennow, K., McEvoy, L. K., & Initiative, A. D. N. (2011) · Neurology · doi:10.1212/wnl.0b013e3182343314 · Cited by 201 · see citing works

Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity

Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Vemuri, P., Mielke, M. M., Jones, D. T., Senjem, M. L., Gunter, J. L., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000435556.21319.e4 · Cited by 200 · see citing works

Cerebrospinal fluid Aβ42 is the best predictor of clinical progression in patients with subjective complaints

van Harten, A. C., Visser, P. J., Pijnenburg, Y. A. L., Teunissen, C. E., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2012.08.004 · Cited by 197 · see citing works

Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer’s disease: a selective review

Rentz, D. M., Parra, M. A., Amariglio, R. E., Stern, Y., Sperling, R. A., & Ferris, S. H. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt222 · Cited by 196 · see citing works

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study

AV45-A11 Study Group, Doraiswamy, P. M., Sperling, R. A., Johnson, K., Reiman, E. M., Wong, T. Z., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., Carpenter, A., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.9 · Cited by 195 · see citing works

Impact of molecular imaging on the diagnostic process in a memory clinic

Ossenkoppele, R., Prins, N. D., Pijnenburg, Y. A. L., Lemstra, A. W., van der Flier, W. M., Adriaanse, S. F., Windhorst, A. D., Handels, R. L. H., Wolfs, C. A. G., Aalten, P., et al. (2013) · Alzheimer's &amp; Dementia · doi:10.1016/j.jalz.2012.07.003 · Cited by 194 · see citing works

Amyloid-Dependent and Amyloid-Independent Stages of Alzheimer Disease

Hyman, B. T. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.70 · Cited by 192 · see citing works

ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project

Ebenau, J. L., Timmers, T., Wesselman, L. M. P., Verberk, I. M. W., Verfaillie, S. C. J., Slot, R. E. R., van Harten, A. C., Teunissen, C. E., Barkhof, F., van den Bosch, K. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009724 · Cited by 191 · see citing works

Alzheimer's Disease: Redox Dysregulation As a Common Denominator for Diverse Pathogenic Mechanisms

Rommy von Bernhardi, M., & Eugenín, J. L. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4082 · Cited by 189 · see citing works

Cross-sectional and Longitudinal Analysis of the Relationship Between Aβ Deposition, Cortical Thickness, and Memory in Cognitively Unimpaired Individuals and in Alzheimer Disease

Doré, V., Villemagne, V. L., Bourgeat, P., Fripp, J., Acosta, O., Chételat, G., Zhou, L., Martins, R. N., Ellis, K. A., Masters, C. L., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.1062 · Cited by 182 · see citing works

Quantitative EEG power and synchronization correlate with Alzheimer's disease CSF biomarkers

Smailovic, U., Koenig, T., Kåreholt, I., Andersson, T., Kramberger, M. G., Winblad, B., & Jelic, V. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.11.005 · Cited by 177 · see citing works

Revised Criteria for Mild Cognitive Impairment May Compromise the Diagnosis of Alzheimer Disease Dementia

Morris, J. C. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3152 · Cited by 176 · see citing works

Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia

Ferrer, I. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.03.005 · Cited by 174 · see citing works

PET amyloid-beta imaging in preclinical Alzheimer's disease

Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 173 · see citing works

Detection and treatment of Alzheimer’s disease in its preclinical stage

Rafii, M. S., & Aisen, P. S. S. (2023) · Nature Aging · doi:10.1038/s43587-023-00410-4 · Cited by 173 · see citing works

Indicators of amyloid burden in a population-based study of cognitively normal elderly

Mielke, M. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Roberts, R. O., Geda, Y. E., Swenson-Dravis, D. M., Boeve, B. F., Senjem, M. L., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e31826e2696 · Cited by 163 · see citing works

APOE modifies the association between Aβ load and cognition in cognitively normal older adults

Kantarci, K., Lowe, V. J., Przybelski, S. A., Weigand, S. D., Senjem, M. L., Ivnik, R. J., Preboske, G. M., Roberts, R. O., Geda, Y. E., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31824365ab · Cited by 159 · see citing works

More than cholesterol transporters: lipoprotein receptors in CNS function and neurodegeneration

Lane-Donovan, C., Philips, G. T., & Herz, J. (2014) · Neuron · doi:10.1016/j.neuron.2014.08.005 · Cited by 158 · see citing works

Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant

Mormino, E. C., Brandel, M. G., Madison, C. M., Rabinovici, G. D., Marks, S., Baker, S. L., & Jagust, W. J. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.07.098 · Cited by 158 · see citing works

Alzheimer's Prevention Initiative: A Proposal to Evaluate Presymptomatic Treatments as Quickly as Possible

Reiman, E. M., Langbaum, J. B. S., & Tariot, P. N. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.91 · Cited by 156 · see citing works

Mapping synaptic glutamate transporter dysfunction in vivo to regions surrounding Aβ plaques by iGluSnFR two-photon imaging

Hefendehl, J. K., LeDue, J. M., Ko, R. W. Y., Mahler, J., Murphy, T. H., & MacVicar, B. A. (2016) · Nature Communications · doi:10.1038/ncomms13441 · Cited by 157 · see citing works

Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease

Kadir, A., Almkvist, O., Forsberg, A., Wall, A. E., Engler, H., Långström, B., & Nordberg, A. K. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.06.015 · Cited by 154 · see citing works

Serial MRI and CSF biomarkers in normal aging, MCI, and AD

Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Trojanowski, J. Q., Shaw, L. M., Bernstein, M. A., Aisen, P. S., Weiner, M., Petersen, R. C., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e7ca82 · Cited by 154 · see citing works

Alzheimer's Disease Neurodegenerative Biomarkers Are Associated with Decreased Cognitive Function but Not β-Amyloid in Cognitively Normal Older Individuals

Wirth, M., Madison, C. M., Rabinovici, G. D., Oh, H., Landau, S. M., & Jagust, W. J. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4409-12.2013 · Cited by 151 · see citing works

Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects

Lim, H. K., Nebes, R. D., Snitz, B. E., Cohen, A. D., Mathis, C. A., Price, J. C., Weissfeld, L. A., Klunk, W. E., & Aizenstein, H. J. (2014) · Brain · doi:10.1093/brain/awu271 · Cited by 148 · see citing works

A Deposition in Aging Is Associated with Increases in Brain Activation during Successful Memory Encoding

Mormino, E. C., Brandel, M. G., Madison, C. M., Marks, S. M., Baker, S. L., & Jagust, W. J. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr255 · Cited by 146 · see citing works

Ushering in the study and treatment of preclinical Alzheimer disease

Langbaum, J. B. S., Fleisher, A., Chen, K., Ayutyanont, N., Lopera, F. J., Quiroz, Y. T., Caselli, R. J., Tariot, P. N., & Reiman, E. M. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.107 · Cited by 145 · see citing works

Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1‐42

Schott, J. M., Bartlett, J. W., Fox, N. C., Barnes, J., & Initiative, A. D. N. (2010) · Annals of Neurology · doi:10.1002/ana.22315 · Cited by 145 · see citing works

Diagnosis and biomarkers of predementia in Alzheimer's disease

Forlenza, O. V., Diniz, B. S., & Gattaz, W. F. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-89 · Cited by 145 · see citing works

Amyloid-β diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis

Lucey, B. P., & Bateman, R. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.035 · Cited by 144 · see citing works

Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data

Vlassenko, A. G., Mintun, M. A., Xiong, C., Sheline, Y. I., Goate, A., Benzinger, T. L. S., & Morris, J. C. (2011) · Annals of Neurology · doi:10.1002/ana.22608 · Cited by 144 · see citing works

Dominantly Inherited Alzheimer Network: facilitating research and clinical trials

Moulder, K. L., Snider, B., Mills, S. L., Buckles, V. D., Santacruz, A. M., Bateman, R. J., & Morris, J. C. (2013) · Alzheimer's Research &amp; Therapy · doi:10.1186/alzrt213 · Cited by 142 · see citing works

Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels

Babulal, G. M., Ghoshal, N., Head, D. M., Vernon, E. K., Holtzman, D. M., Benzinger, T. L. S., Fagan, A. M., Morris, J. C., & Roe, C. M. (2016) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.04.004 · Cited by 142 · see citing works

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020

Hampel, H. J., Lista, S., Teipel, S. J., Garaci, F., Nisticò, R., Blennow, K., Zetterberg, H., Bertram, L., Duyckaerts, C. J., Bakardjian, H., et al. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.009 · Cited by 141 · see citing works

Characterization of AZD4694, a novel fluorinated Aβ plaque neuroimaging PET radioligand

Juréus, A., Swahn, B., Sandell, J., Jeppsson, F., Johnson, A. E., Johnström, P., Neelissen, J. A. M., Sunnemark, D., Farde, L., & Svensson, S. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06812.x · Cited by 140 · see citing works

Seeded strain‐like transmission of β‐amyloid morphotypes in APP transgenic mice

Heilbronner, G., Eisele, Y. S., Langer, F., Kaeser, S. A., Novotny, R., Nagarathinam, A., Åslund, A., Hammarström, P., Nilsson, K. P. R., & Jucker, M. (2013) · EMBO Reports · doi:10.1038/embor.2013.137 · Cited by 139 · see citing works

Sleep and β-Amyloid Deposition in Alzheimer Disease: Insights on Mechanisms and Possible Innovative Treatments

Cordone, S., Annarumma, L., Rossini, P. M., & Gennaro, L. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00695 · Cited by 139 · see citing works

Biomarkers for Alzheimer's disease therapeutic trials

Hampel, H. J., Wilcock, G. K., Andrieu, S., Aisen, P. S. S., Blennow, K., Broich, K., Carrillo, M. C., Fox, N. C., Frisoni, G. B., Isaac, M., et al. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.11.005 · Cited by 137 · see citing works

3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects

Apostolova, L. G., Hwang, K., Andrawis, J. P., Green, A. E., Babakchanian, S., Morra, J. H., Cummings, J. L., Toga, A. W., Trojanowski, J. Q., Shaw, L. M. J., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.003 · Cited by 137 · see citing works

P4‐080: Predicting Symptomatic Alzheimer's Disease in Healthy Individuals With Amyloid Imaging

Morris, J. C., Roe, C. M., & Mintun, M. A. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.08.141

IC‐P‐051: Longitudinal increases in PiB are associated with temporal lobe cortical volume loss in asymptomatic participants

Benzinger, T. L. S., D’Angelo, G., Blazey, T., Zhou, G., Ances, B. M., Vlassenko, A. G., & Morris, J. C. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.084

P4‐188: Longitudinal increases in PiB are associated with temporal lobe cortical volume loss in asymptomatic participants

Benzinger, T. L. S., D’Angelo, G., Blazey, T., Zhou, G., Ances, B. M., Vlassenko, A. G., & Morris, J. C. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.1892

Postmortem Pittsburgh Compound B (PiB) Binding Increases with Alzheimer's Disease Progression

Beckett, T. L., Webb, R. L., Niedowicz, D. M., Holler, C. J., Matveev, S., Baig, I., LeVine, H., Keller, J. N., & Murphy, M. P. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120655 · Cited by 18 · see citing works

Amyloid imaging in prodromal Alzheimer's disease

Ossenkoppele, R., van Berckel, B. N. M., & Prins, N. D. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt88 · Cited by 27 · see citing works